{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:48:55Z","timestamp":1792097335403,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03828-5","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:40:26Z","timestamp":1792096826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Effectiveness and Safety of Advanced Combination Treatment in Patients with Refractory Inflammatory Bowel Disease"],"prefix":"10.1007","author":[{"given":"Enas Fouad","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille Conde","family":"Oribiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam A.","family":"Alahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeen Mamon","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishore Kumar","family":"Chitra Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1673-7792","authenticated-orcid":false,"given":"Mohammed Nabil","family":"Quraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"3828_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S2468-1253(21)00065-0","volume":"6","author":"D Alsoud","year":"2021","unstructured":"Alsoud D, Verstockt B, Fiocchi C, Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol. 2021;6:589\u201395. https:\/\/doi.org\/10.1016\/S2468-1253(21)00065-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3828_CR2","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1053\/j.gastro.2021.09.078","volume":"162","author":"T Raine","year":"2022","unstructured":"Raine T, Danese S. Breaking through the therapeutic ceiling: what will it take? Gastroenterology. 2022;162:1507\u201311. https:\/\/doi.org\/10.1053\/j.gastro.2021.09.078.","journal-title":"Gastroenterology"},{"key":"3828_CR3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S2468-1253(23)00154-1","volume":"8","author":"TL Parigi","year":"2023","unstructured":"Parigi TL, D\u2019Amico F, Abreu MT, Dignass A, Dotan I, Magro F, et al. Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting. Lancet Gastroenterol Hepatol. 2023;8:853\u20139. https:\/\/doi.org\/10.1016\/S2468-1253(23)00154-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3828_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae145","volume":"19","author":"TL Parigi","year":"2025","unstructured":"Parigi TL, Massimino L, Carini A, Gabbiadini R, Bertoli P, Allocca M, et al. Prevalence, characteristics, management, and outcomes of difficult-to-treat inflammatory Bowel disease. J Crohn\u2019s Colitis. 2025;19:jjae145. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae145.","journal-title":"J Crohn\u2019s Colitis."},{"key":"3828_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103582","volume":"89","author":"V Solitano","year":"2025","unstructured":"Solitano V, Han\u017eel J, Ma C, Battat R, Raine T, Siegmund B, et al. An international consensus on the design of clinical trials for advanced combination treatment (ACT) in inflammatory bowel disease. eClinicalMedicine. 2025;89:103582. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103582.","journal-title":"eClinicalMedicine"},{"key":"3828_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","volume":"8","author":"BG Feagan","year":"2023","unstructured":"Feagan BG, Sands BE, Sandborn WJ, Germinaro M, Vetter M, Shao J, et al. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023;8:307\u201320. https:\/\/doi.org\/10.1016\/S2468-1253(22)00427-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3828_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/jebm.70157","author":"C Xu","year":"2026","unstructured":"Xu C, Huang X, Zong Y, Li P, Zhang S, Shi H. Dual targeted therapy for refractory inflammatory bowel disease: a systematic review and meta\u2010analysis. J Evid Based Med. 2026. https:\/\/doi.org\/10.1111\/jebm.70157.","journal-title":"J Evid Based Med"},{"key":"3828_CR8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.14309\/ajg.0000000000003573","volume":"121","author":"V Solitano","year":"2026","unstructured":"Solitano V, Ogunsakin RE, Yuan Y, Bernstein CN, Bessissow T, Bressler B, et al. Effectiveness and safety of advanced combination treatment in patients with refractory inflammatory bowel disease or concomitant immune-mediated disease or extraintestinal manifestations: a multicenter Canadian study. Am J Gastroenterol. 2026;121:410\u201323. https:\/\/doi.org\/10.14309\/ajg.0000000000003573.","journal-title":"Am J Gastroenterol"},{"key":"3828_CR9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.dld.2024.08.055","volume":"57","author":"C McShane","year":"2025","unstructured":"McShane C, Varley R, Fennessy A, Byron C, Campion JR, Hazel K, et al. Effectiveness, safety, and cost of combination advanced therapies in inflammatory bowel disease. Dig Liver Dis. 2025;57:274\u201381. https:\/\/doi.org\/10.1016\/j.dld.2024.08.055.","journal-title":"Dig Liver Dis"},{"key":"3828_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otae057","volume":"7","author":"S Bhaskar","year":"2024","unstructured":"Bhaskar S, Makovich Z, Mhaskar R, Coughlin E, Seminerio-Diehl J. Exploring dual-targeted therapy in the management of moderate to severe inflammatory bowel disease: a retrospective study. Crohns Colitis 360. 2024;7:otae057. https:\/\/doi.org\/10.1093\/crocol\/otae057.","journal-title":"Crohns Colitis 360"},{"key":"3828_CR11","doi-asserted-by":"publisher","first-page":"S-2855","DOI":"10.1016\/S0016-5085(26)06752-1","volume":"170","author":"BE Sands","year":"2026","unstructured":"Sands BE, D\u2019Haens G, Dotan I, Terry NA, Walker M, Bundy V, et al. 979f Efficacy and safety of the first co-antibody therapy, JNJ-78934804, in patients with moderately to severely active Crohn\u2019s disease refractory to systemic therapies. Gastroenterology. 2026;170:S-2855-S\u22122856. https:\/\/doi.org\/10.1016\/S0016-5085(26)06752-1.","journal-title":"Gastroenterology"},{"key":"3828_CR12","doi-asserted-by":"publisher","first-page":"S-2857","DOI":"10.1016\/S0016-5107(26)06687-3","volume":"103","author":"MT Abreu","year":"2026","unstructured":"Abreu MT, Sands BE, Vermeire S, Panaccione R, Moore G, Atreya R, et al. 1058d Efficacy and safety of the first co-antibody therapy, JNJ-78934804, in patients with moderately to severely active ulcerative colitis refractory to systemic therapies. Gastrointest Endosc. 2026;103:S-2857-S\u22122858. https:\/\/doi.org\/10.1016\/S0016-5107(26)06687-3.","journal-title":"Gastrointest Endosc"},{"key":"3828_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2025.101574","volume":"48","author":"S Danese","year":"2025","unstructured":"Danese S, Sands BE, Feagan BG, Jairath V, Panaccione R, Peyrin-Biroulet L, et al. Design and rationale for the VICTRIVA study: a randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn\u2019s disease. Contemp Clin Trials Commun. 2025;48:101574. https:\/\/doi.org\/10.1016\/j.conctc.2025.101574.","journal-title":"Contemp Clin Trials Commun"},{"key":"3828_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S2468-1253(25)00346-2","volume":"11","author":"M Shehab","year":"2026","unstructured":"Shehab M, Al-Hindawi A, Goodwin SW, Yuan Y, Bessissow T, Peyrin-Biroulet L, et al. Closing the Middle East and North Africa representation gap in clinical trials in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2026;11:89\u201391. https:\/\/doi.org\/10.1016\/S2468-1253(25)00346-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3828_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2025-002034","volume":"12","author":"MN Quraishi","year":"2025","unstructured":"Quraishi MN, Alahmad MA, Sharara AI, Trivedi PJ, Al-Bawardy B, Alrubaiy L. Utilisation and real-world effectiveness of advanced therapies for inflammatory bowel disease in Middle Eastern populations: a systematic review. BMJ Open Gastroenterol. 2025;12:e002034. https:\/\/doi.org\/10.1136\/bmjgast-2025-002034.","journal-title":"BMJ Open Gastroenterol"},{"key":"3828_CR16","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2026.00032","author":"TK Swaid","year":"2026","unstructured":"Swaid TK, Hamzeh LR, Bukasa LL, Jess T, Quraishi MN. Rapid diagnosis and therapeutic mitigation in inflammatory bowel disease: utilizing the window of opportunity\u2013findings from the UAE Epi-IBD study. Intest Res. 2026. https:\/\/doi.org\/10.5217\/ir.2026.00032.","journal-title":"Intest Res"},{"key":"3828_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otag057","author":"H Abdelrahman Ahmed","year":"2026","unstructured":"Abdelrahman Ahmed H, Alzaabi MN, Swai TK, Khan SW, Al Hosani M, Al Hosani N, et al. Paradigm shift in inflammatory bowel disease management\u2014advanced therapy utilisation, persistence, and outcomes in a United Arab Emirates cohort during 2015\u20132025. Crohn\u2019s Colitis 360. 2026. https:\/\/doi.org\/10.1093\/crocol\/otag057.","journal-title":"Crohn\u2019s Colitis 360."},{"key":"3828_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otaf062","volume":"7","author":"MN Alzaabi","year":"2025","unstructured":"Alzaabi MN, Swaid TK, Ahmed HA, Alahmad MA, Omar NM, Chitra Kumar KK, et al. Real-world effectiveness of Risankizumab in Crohn\u2019s disease: outcome data for an IL-23 inhibitor from the Middle East. Crohns Colitis 360. 2025;7:otaf062. https:\/\/doi.org\/10.1093\/crocol\/otaf062.","journal-title":"Crohns Colitis 360."},{"key":"3828_CR19","doi-asserted-by":"publisher","first-page":"5A","DOI":"10.1155\/2005\/269076","volume":"19","author":"MS Silverberg","year":"2005","unstructured":"Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5A-36A. https:\/\/doi.org\/10.1155\/2005\/269076.","journal-title":"Can J Gastroenterol"},{"key":"3828_CR20","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","volume":"315","author":"RF Harvey","year":"1980","unstructured":"Harvey RF, Bradshaw JM. A simple index of Crohn\u2019s-disease activity. Lancet. 1980;315:514. https:\/\/doi.org\/10.1016\/S0140-6736(80)92767-1.","journal-title":"Lancet"},{"key":"3828_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/gut.43.1.29","volume":"43","author":"RS Walmsley","year":"1998","unstructured":"Walmsley RS, Ayres RCS, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43:29\u201332. https:\/\/doi.org\/10.1136\/gut.43.1.29.","journal-title":"Gut"},{"key":"3828_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno M, D\u2019Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD. Gastrointest Endosc. 2004;60:505\u201312. https:\/\/doi.org\/10.1016\/S0016-5107(04)01878-4.","journal-title":"Gastrointest Endosc"},{"key":"3828_CR23","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 1987;317:1625\u20139. https:\/\/doi.org\/10.1056\/NEJM198712243172603.","journal-title":"N Engl J Med"},{"key":"3828_CR24","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.2147\/JIR.S511309","volume":"18","author":"M-J Meng","year":"2025","unstructured":"Meng M-J, Kuo C-J, Lai M-W, Chiu C-T, Su M-Y, Chang M-L, et al. Advanced combination therapy with biologics and upadacitinib in refractory inflammatory bowel disease: a retrospective study from Taiwan. JIR. 2025;18:2733\u201342. https:\/\/doi.org\/10.2147\/JIR.S511309.","journal-title":"JIR"},{"key":"3828_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goag088","volume":"14","author":"MN Quraishi","year":"2026","unstructured":"Quraishi MN, Ben Ghashir N, Mheidly K. Sustained drug-free remission of refractory ulcerative colitis following rituximab therapy for Epstein-Barr virus-positive mucocutaneous ulcer. Gastroenterol Rep. 2026;14:goag088. https:\/\/doi.org\/10.1093\/gastro\/goag088.","journal-title":"Gastroenterol Rep"},{"key":"3828_CR26","doi-asserted-by":"publisher","first-page":"475","DOI":"10.5217\/ir.2024.00174","volume":"23","author":"R Gilmore","year":"2025","unstructured":"Gilmore R, Murali A, Etchegaray A, Swe E, An Y-K, Begun J. Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn\u2019s disease. Intest Res. 2025;23:475\u201382. https:\/\/doi.org\/10.5217\/ir.2024.00174.","journal-title":"Intest Res"},{"key":"3828_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-026-09995-3","author":"N Natt","year":"2026","unstructured":"Natt N, Choi D, Shafrir A, Dalal SR, Krugliak Cleveland N, Cohen RD, et al. Combining guselkumab with upadacitinib is safe and effective in the treatment of medically complex inflammatory bowel disease. Dig Dis Sci. 2026. https:\/\/doi.org\/10.1007\/s10620-026-09995-3.","journal-title":"Dig Dis Sci"},{"key":"3828_CR28","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/ajg.2015.120","volume":"110","author":"MH Mosli","year":"2015","unstructured":"Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110:802\u201319. https:\/\/doi.org\/10.1038\/ajg.2015.120.","journal-title":"Am J Gastroenterol"},{"key":"3828_CR29","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ueg2.12581","volume":"12","author":"SR Fernandes","year":"2024","unstructured":"Fernandes SR, Bernardo S, Saraiva S, Gon\u00e7alves AR, Moura Santos P, Valente A, et al. The degree of bowel remission predicts phenotype progression in Crohn\u2019s disease. UEG J. 2024;12:891\u2013900. https:\/\/doi.org\/10.1002\/ueg2.12581.","journal-title":"UEG J"},{"key":"3828_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cgh.2023.08.039","volume":"22","author":"DJ Katibian","year":"2024","unstructured":"Katibian DJ, Solitano V, Polk DB, Nguyen T, Ma C, Syal G, et al. Withdrawal of immunomodulators or TNF antagonists in patients with inflammatory bowel diseases in remission on combination therapy: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2024;22:22-33.e6. https:\/\/doi.org\/10.1016\/j.cgh.2023.08.039.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3828_CR31","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1002\/cpt.3235","volume":"115","author":"J Shao","year":"2024","unstructured":"Shao J, Vetter M, Vermeulen A, Feagan BG, Sands BE, Pan\u00e9s J, et al. Combination therapy with guselkumab and golimumab in patients with moderately to severely active ulcerative colitis: pharmacokinetics, immunogenicity and drug\u2013drug interactions. Clin Pharma Ther. 2024;115:1418\u201327. https:\/\/doi.org\/10.1002\/cpt.3235.","journal-title":"Clin Pharma Ther"},{"key":"3828_CR32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S2468-1253(21)00223-5","volume":"7","author":"K Papamichael","year":"2022","unstructured":"Papamichael K, Afif W, Drobne D, Dubinsky MC, Ferrante M, Irving PM, et al. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol. 2022;7:171\u201385. https:\/\/doi.org\/10.1016\/S2468-1253(21)00223-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"3828_CR33","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1097\/MIB.0000000000000138","volume":"20","author":"MT Frederiksen","year":"2014","unstructured":"Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen O\u00d8, Bendtzen K, Steenholdt C. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Inflamm Bowel Dis. 2014;20(10):1714\u201321. https:\/\/doi.org\/10.1097\/MIB.0000000000000138.","journal-title":"Inflamm Bowel Dis."},{"key":"3828_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2026-002347","volume":"13","author":"SW Khan","year":"2026","unstructured":"Khan SW, Al Hosani N, Swaid TK, Edan MM, Quraishi MN. Anti-TNF immunogenicity in a Middle Eastern inflammatory bowel disease cohort: prevalence, predictors and context-specific drug level thresholds. BMJ Open Gastroenterol. 2026;13:e002347. https:\/\/doi.org\/10.1136\/bmjgast-2026-002347.","journal-title":"BMJ Open Gastroenterol"},{"key":"3828_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/PAS.0b013e3181cf8622","volume":"34","author":"SD Dojcinov","year":"2010","unstructured":"Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES. EBV positive mucocutaneous ulcer\u2014a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol. 2010;34:405\u201317. https:\/\/doi.org\/10.1097\/PAS.0b013e3181cf8622.","journal-title":"Am J Surg Pathol"},{"key":"3828_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2026.06.003","author":"A Meyer","year":"2026","unstructured":"Meyer A, Weill A, Carbonnel F, Dray-Spira R. Risk of lymphoma associated with biologics and immunosuppressants in inflammatory bowel disease patients: a nationwide nested case-control study. Clin Gastroenterol Hepatol. 2026. https:\/\/doi.org\/10.1016\/j.cgh.2026.06.003.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3828_CR37","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","volume":"318","author":"M Lemaitre","year":"2017","unstructured":"Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679. https:\/\/doi.org\/10.1001\/jama.2017.16071.","journal-title":"JAMA"},{"key":"3828_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2026-002307","volume":"13","author":"S Radford","year":"2026","unstructured":"Radford S, Albuquerque DAN, Najeeb Z, Agarwal D, John A, Gordon M, et al. Safety and efficacy of advanced combination therapies for treating inflammatory bowel disease in adults: a systematic review and meta-analysis. BMJ Open Gastroenterol. 2026;13:e002307. https:\/\/doi.org\/10.1136\/bmjgast-2026-002307.","journal-title":"BMJ Open Gastroenterol"},{"key":"3828_CR39","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2025.00325","author":"H-Y Wu","year":"2026","unstructured":"Wu H-Y, Chen Z-C, Weng M-T, Ho AHY, Mak JWY, Leong RW, et al. Real-world use and perceptions of advanced combined therapies in treating inflammatory bowel disease. Intest Res. 2026. https:\/\/doi.org\/10.5217\/ir.2025.00325.","journal-title":"Intest Res"},{"key":"3828_CR40","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.14309\/ajg.0000000000003397","volume":"120","author":"J-C Yang","year":"2025","unstructured":"Yang J-C, Janssen EM, Wallace MJ, Sheahan A, Lynch J, Bewtra M, et al. Quantifying patient preferences for risk tolerance with novel dual biologic therapies for inflammatory bowel disease. Am J Gastroenterol. 2025;120:2848\u201356. https:\/\/doi.org\/10.14309\/ajg.0000000000003397.","journal-title":"Am J Gastroenterol"},{"key":"3828_CR41","doi-asserted-by":"publisher","unstructured":"Soldera J, Pertile MAS, Carobin LN, Brambilla DJF, Brambilla E. Beyond class switching in multi-refractory inflammatory bowel disease: nine case reports and review of literature. World J Gastrointest Pharmacol Ther [Internet]. 2026 [cited 2026 Sept 22];17. https:\/\/doi.org\/10.4292\/wjgpt.120771.","DOI":"10.4292\/wjgpt.120771"},{"key":"3828_CR42","doi-asserted-by":"publisher","first-page":"5468","DOI":"10.12998\/wjcc.v12.i24.5468","volume":"12","author":"J Soldera","year":"2024","unstructured":"Soldera J. Navigating treatment resistance: Janus kinase inhibitors for ulcerative colitis. World J Clin Cases. 2024;12:5468\u201372. https:\/\/doi.org\/10.12998\/wjcc.v12.i24.5468.","journal-title":"World J Clin Cases"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03828-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03828-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03828-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:40:27Z","timestamp":1792096827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03828-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":42,"alternative-id":["3828"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03828-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"4 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Enas Fouad Ahmed, Camille Conde Oribiana, Maryam A. Alahmad, Nadeen Mamon Omar and Kishore Kumar Chitra Kumar have nothing to disclose. Mohammed Nabil Quraishi has received speaker fees from Johnson and Johnson, Takeda, AbbVie, Eli Lilly, Hikma Pharmaceuticals and Abbott, and consultancy fees from Johnson and Johnson, AbbVie, MSD, Alpha Clinical Development and Eli Lilly. Mohammed Nabil Quraishi is an Editorial Board member of Advances in Therapy. Mohammed Nabil Quraishi was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the SSMC Research Ethics Committee (reference SSMCREC-585, approved 2 March 2025). The requirement for individual informed consent was waived, as the analysis used routinely collected data held in an approved clinical registry.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}